Thornburg Investment Management Inc. Sells 9,009,301 Shares of Pfizer Inc. $PFE

Thornburg Investment Management Inc. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 86.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 1,449,270 shares of the biopharmaceutical company’s stock after selling 9,009,301 shares during the period. Thornburg Investment Management Inc.’s holdings in Pfizer were worth $36,927,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer during the 3rd quarter worth about $29,000. Howard Hughes Medical Institute bought a new position in Pfizer in the 2nd quarter valued at about $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer during the second quarter worth approximately $32,000. Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer during the second quarter worth approximately $33,000. Finally, True Wealth Design LLC grew its position in shares of Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1%

Shares of PFE opened at $27.11 on Thursday. The firm has a 50 day simple moving average of $26.04 and a two-hundred day simple moving average of $25.37. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a market cap of $154.11 billion, a P/E ratio of 19.93 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The business’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.63 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PFE. HSBC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. UBS Group assumed coverage on shares of Pfizer in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 target price for the company. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. Citigroup assumed coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price objective for the company. Finally, Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $27.70.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: FDA gives full approval to Pfizer’s BRAFTOVI combination for first‑line metastatic colorectal cancer — a clear commercial positive for oncology revenue and uptake. Read More.
• Positive Sentiment: Pfizer secures China commercialization partner (Sciwind) for a next‑generation weight‑loss GLP‑1 candidate, expanding market access in a high‑growth obesity/diabetes segment and unlocking up to ~$495M in deal value. Read More.
• Positive Sentiment: Dividend narratives strengthen investor interest — coverage pieces highlight Pfizer’s high yield and management’s commitment to the payout, supporting income‑oriented demand. Read More.
• Neutral Sentiment: Pfizer updated clinical activity in China (pneumococcal vaccine Phase 1) — constructive for long‑term vaccine opportunity but near‑term commercial impact is unclear. Read More.
• Neutral Sentiment: Industry pieces and comparisons (Novo Nordisk, J&J, large‑cap pharma commentary) are placing Pfizer within a broader sector narrative about defensiveness and AI‑driven R&D — useful context but not company‑specific catalysts. Read More.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform/“$25” target and warned of an expected $15B–$20B structural revenue decline through 2030 — a significant bearish forecast that pressures valuation expectations. Read More.
• Negative Sentiment: Zacks moved Pfizer from “strong sell” to “hold,” improving its tone but reflecting continued analyst caution; RBC/other outlets are still negative which keeps analyst sentiment mixed. Read More.
• Negative Sentiment: Pfizer terminated an early‑stage ulcerative colitis study (Phase 1b), representing a pipeline setback and incremental downside risk to future growth prospects. Read More.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.